Novavax faces uncertainty as FDA requests a new clinical trial for its COVID-19 vaccine, the last protein-based option in the ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Wall Street analysts expect Moderna (MRNA) to post quarterly loss of $2.92 per share in its upcoming report, which indicates a year-over-year increase of 4.9%. Revenues are expected to be $126.98 ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...